XUANZHUBIO-B (02575) released its interim results, with revenue of 69.4 million yuan, an increase of 288.1% year-on-year, advancing through four main lines in synergy.

XUANZHUBIO-B (02575) announced its performance for the six months ending June 30, 2026, reporting revenue of 69.4 million yuan, a year-on-year increase of 288.1%; the loss attributable to the owners of the parent company was 75.34 million yuan, narrowing by 32.07% year-on-year; basic loss per share was 0.15 yuan. The announcement stated that the revenue growth was primarily driven by sales growth from the launch of new products and their inclusion in the national basic medical insurance drug list. During the reporting period, the Group advanced its overall business along four main lines: commercialization, clinical development, early-stage R&D, and business development (BD) in a coordinated manner, achieving good progress overall: on the commercialization front, the distribution network and academic recognition of three marketed products continued to improve; on the clinical front, key research milestones were reached for several core products; on the early-stage R&D front, the capabilities of the technology platform were continuously expanded, with multiple new projects completed; on the BD front, external licensing and introduction efforts were made in both directions, securing substantial breakthroughs in global expansion.